Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ended Thursday session in red amid volatile trading. The shares closed down -0.77 points or -2.84% at $26.33 with 14.36 million shares getting traded. Post opening the session at $27.17, the shares hit an intraday low of $26.28 and an intraday high of $27.23 and the price vacillated in this range throughout the day. The company has a market cap of $8.93 billion and the numbers of outstanding shares have been calculated to be 341.19 million shares.
On Sept. 6, 2016 Valeant Pharmaceuticals International, Inc. (VRX) and Progenics Pharmaceuticals, Inc. (PGNX) announced the U.S. commercial launch of RELISTOR® (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016 .
“We are very pleased to launch RELISTOR Tablets in the U.S. and provide an exceptional new treatment option for the millions of patients who suffer from extreme discomfort due to OIC,” said Joseph C. Papa , Chief Executive Officer of Valeant. “This new method of delivery for RELISTOR offers healthcare professionals a novel alternative to address the treatment of OIC – a growing need in pain management – and demonstrates Valeant’s continued commitment to delivering innovative products that improve people’s lives.”
Shares of Novavax, Inc. (NASDAQ:NVAX) ended Thursday session in red amid volatile trading. The shares closed down -0.03 points or -2.01% at $1.46 with 30.34 million shares getting traded. Post opening the session at $1.49, the shares hit an intraday low of $1.39 and an intraday high of $1.52 and the price vacillated in this range throughout the day. The company has a market cap of $457.32 million and the numbers of outstanding shares have been calculated to be 271.19 million shares.
Novavax, Inc. (NVAX) announced it will host its 4th annual Investor and Analyst Meeting, Tuesday, October 11, 2016 from 9:00 a.m. – 11:00 a.m. ET in New York, NY.
Senior management will conduct a series of presentations to update analysts and investors on the Company`s ongoing clinical development programs. In addition, a key opinion leader will provide a clinical perspective on respiratory syncytial virus (RSV) disease.
Novavax expects to announce data from its pivotal Phase 3 trial of the RSV F Vaccine in older adults in the third quarter of 2016.
For additional information and registration, please email email@example.com or call 443-213-0506.
A live webcast of the presentations can be accessed under the “Investors”/ “Events” section of the Novavax website at novavax.com. Please allow extra time prior to the webcast to visit the site and download the streaming media software required to listen to the Internet broadcast. The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com. The event will be archived on the company`s website for 90 days.